$35 Million Growth Round to Fuel OptiMedica’s Leadership in Laser Cataract Surgery

  $35 Million Growth Round to Fuel OptiMedica’s Leadership in Laser Cataract
  Surgery

Business Wire

SUNNYVALE, Calif. -- November 16, 2012

OptiMedica Corp. has announced the closing of a $35 million growth round of
financing. Proceeds will be used to continue the rapid global
commercialization of the company’s Catalys® Precision Laser System for
cataract surgery, support the development of innovative system enhancements,
and fuel a next-generation portfolio of additional products. The round drew
participation from all of OptiMedica’s existing venture backers, which include
Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock
Private Equity Partners and Bio*One Capital – an esteemed group that together
have more than $3.5 trillion under management.

“OptiMedica has been committed to bringing the precision and safety benefits
of femtosecond laser technology to cataract surgery since our founding in
2004. Today, we are literally standing at the forefront of a landscape shift
in the field that, we believe, will ultimately make the laser the centerpiece
of the procedure,” said Mark J. Forchette, OptiMedica president and chief
executive officer. “Catalys has been shown in both clinical practice and
clinical studies to deliver unparalleled precision and performance, with
results and customer satisfaction that lead the industry. Our exceptional
laser technology has enabled surgeons to achieve consistently excellent
clinical results and explore a broad new area of innovation in the field. We
are actively engaged in this exploration and look forward to a long future of
scientific leadership that will continue to bring untold benefits to cataract
surgeons and their patients.”

OptiMedica’s Catalys is U.S. FDA market cleared and CE mark approved for
performing every step of the laser cataract procedure. Since its international
launch in November 2011 and its U.S. launch in February 2012, the system has
been installed at leading ophthalmic practices in 10 countries and used to
perform more than 6,000 laser cataract procedures worldwide. Surgeons have
reported exceptional results with Catalys, including complete capsulotomies in
99 to 100 percent of procedures^1, elimination of ultrasound energy during
lens disassembly and removal^2, and exceptionally precise corneal incisions^3.
They have also reported little to no learning curve with the system.

“The rapid worldwide adoption of Catalys is not only a direct result of the
system’s unparalleled performance but also of the amazing talent and unique
Silicon Valley culture that you’ll find at OptiMedica,” said Brook Byers,
partner, Kleiner Perkins Caufield & Byers, and chairman of the board,
OptiMedica. “This is a company with a proven track record of delivering
innovation that transforms existing standards of care. We are very
enthusiastic about OptiMedica’s long-term prospects to lead the field of
cataract surgery and continue to drive better results for cataract surgeons
and their patients.”

About Catalys

Catalys is a next generation laser cataract surgery platform that combines a
femtosecond laser, integrated 3D Optical Coherence Tomography (OCT) imaging,
and OptiMedica’s breakthrough pattern scanning technology in an ergonomic,
easy-to-use system. Distinguishing features include a Liquid Optics™ Interface
that ensures stable system-patient attachment and optimizes the optical path
to the patient’s eye, and a proprietary Integral Guidance™ mapping system that
ensures the femtosecond laser pulses are delivered safely and precisely to the
intended location. In addition, Catalys features an easy-to-use and elegant
graphical user interface designed to simplify the planning process and
minimize the time the patient is under the dock.

About OptiMedica

Founded in 2004 and headquartered in Sunnyvale, Calif., OptiMedica Corp. is
Silicon Valley-based global ophthalmic device company dedicated to developing
performance-driven technologies that improve patient outcomes. Exclusively
focused in the cataract therapeutic area, the company has developed the
Catalys Precision Laser System to transform existing standards of care in
cataract surgery.

OptiMedica’s legacy of innovation in ophthalmology also includes the
development and commercialization of the PASCAL® Method of retinal
photocoagulation, which was acquired by Topcon Corp. in August 2010. The
company is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG
Ventures, BlackRock Private Equity Partners and Bio*One Capital. For more
information, please visit www.optimedica.com.

References

^1 Dick, BH. “Femtosecond cataract surgery outcomes: an advance or not?” XXX
Congress of the ESCRS, Sept. 2012.
^2 Dick, BH. “Femtosecond cataract surgery outcomes: an advance or not?” XXX
Congress of the ESCRS, Sept. 2012.
^3 Culbertson, B. “Optimization of corneal incision parameters with a
femtosecond laser for cataract surgery.” XXX Congress of the ESCRS, Sept.
2012.

Contact:

Nobles Communications
Laura Nobles, 310-795-0497
laura@noblescommunications.com